Elicit: Resistance Mechanisms in Enzalutamide Therapy
Resistance Mechanisms in Enzalutamide Therapy
What resistance mechanisms emerge during enzalutamide therapy?
Enzalutamide resistance mechanisms include AR pathway alterations (amplifications, mutations, splice variants), bypass signaling pathways (JAK2-STAT5, glucocorticoid receptor), metabolic adaptations (AKR1C3, HMGCR), and lineage plasticity, primarily through clonal selection of pre-existing heterogeneity rather than newly acquired mutations.
Abstract
Resistance to enzalutamide in castration-resistant prostate cancer involves multiple mechanisms operating at both androgen receptor-dependent and AR-independent levels. AR pathway alterations represent the most extensively validated resistance mechanisms, with AR amplifications increasing from 53.9% at baseline to 64.7% at progression, specific AR mutations (H875Y, F877L, T878A/S) detected in approximately 15% of patients with progressive disease, and AR-V7 splice variants rising from 29% at baseline to 40% during treatment. However, a substantial proportion of resistance mechanisms are pre-existing rather than purely acquired, with 73.1% of baseline biopsies showing AR pathway alterations and 92.3% harboring tumor suppressor mutations (PTEN, RB1, TP53), indicating that clonal selection during treatment intensifies pre-existing heterogeneity. Bypass signaling pathways emerge as alternative resistance mechanisms, including JAK2-STAT5 activation through a positive feed-forward loop induced by enzalutamide-liganded AR, glucocorticoid receptor upregulation confirmed in clinical samples, and metabolic adaptations involving AKR1C3 and HMGCR that enable intracrine androgen synthesis. The spectrum of resistance mechanisms varies by prior treatment exposure, with specific AR mutations (L702H, T878A) enriched in abiraterone-pretreated patients, and by disease duration, with lineage plasticity toward neuroendocrine differentiation emerging under sustained AR suppression. Therapeutic strategies targeting these mechanisms include combination approaches with PARP inhibitors (TALAPRO-2 trial), EZH2 inhibitors (MEVPRO-2 trial), JAK2 inhibitors, and metabolic pathway inhibitors including statins and indomethacin, though patient selection based on molecular profiling remains critical for matching resistance mechanisms to targeted interventions.
Results
Characteristics of Included Studies
The included studies comprise six reviews and four primary studies examining resistance mechanisms to enzalutamide in castration-resistant prostate cancer. Full text was available for six studies, while four studies were available as abstract only. The evidence types varied substantially, with most studies employing multiple complementary approaches including cell line models, patient tissue samples, circulating biomarkers, and animal models.
Resistance Mechanisms
Androgen Receptor-Dependent Mechanisms
Multiple studies identified alterations in the androgen receptor (AR) itself as central to enzalutamide resistance. These mechanisms maintain AR signaling despite enzalutamide treatment through various molecular alterations.
| Mechanism | Type of Alteration | Clinical Validation | Timing of Emergence |
|---|---|---|---|
| AR amplification | Copy number gain | Detected in 53.9% at baseline, 64.7% at progression; associated with worse progression-free survival (HR 2.92) | Both pre-existing and acquired |
| AR mutations (H875Y, F877L, T878A/S) | Point mutations in ligand-binding domain | Observed in ~15% of progressive mCRPC patients; F877L and T878A mutations increase during treatment | Primarily acquired during treatment |
| AR splice variants (AR-V7) | Constitutively active truncated variants | Detected in 29% at baseline, 40% at progression; associated with shorter survival and lower PSA response rates | Both pre-existing and acquired |
| Heavily mutated AR (≥2 mutations) | Multiple mutations | Associated with worse progression-free survival (HR 3.94) | Acquired during treatment |
Bypass Signaling Pathways
Several studies identified alternative signaling pathways that circumvent AR inhibition, enabling tumor growth despite enzalutamide treatment.
- Glucocorticoid Receptor Pathway: Glucocorticoid receptor (GR) upregulation activates AR target genes through an alternative pathway.
- JAK2-STAT5 Signaling: Enzalutamide-liganded AR induces sustained JAK2-STAT5 phosphorylation, creating a feed-forward loop where activated STAT5 increases JAK2 mRNA and protein levels.
- PI3K/Akt/mTOR Pathway: AR inhibition increases active Akt, which activates oncogenic pathways and rescues AR protein levels.
- Additional Bypass Pathways: Noncanonical Wnt signaling through Wnt5A observed in resistant cells, with CTNNB1 mutations enhancing tumor growth despite enzalutamide.
Tumor Suppressor Loss and Lineage Plasticity
| Alteration | Frequency | Clinical Correlation | Mechanism |
|---|---|---|---|
| PTEN loss | Present in 92.3% of baseline biopsies | Associated with resistance | Affects AR signaling pathway |
| RB1 loss | Present in 92.3% of baseline biopsies; 13/63 samples | Associated with worse progression-free survival (HR 4.46) | Drives lineage plasticity toward AR-independent neuroendocrine phenotype |
| TP53 loss | Present in 92.3% of baseline biopsies | Associated with resistance | Combined knockdown with RB1 leads to resistance |
| BRCA2 alterations | 38.5% at baseline, 64.7% at progression | Increased post-enzalutamide | May enable tumor survival despite DNA damage |
Tumor Microenvironment and Immune Mechanisms
The tumor microenvironment is characterized by reduced infiltration of cytotoxic immune cells and altered cytokine expression profiles. IL6 from the tumor microenvironment activates the JAK/STAT3 pathway, promoting resistance. Immune evasion through PD-L1 upregulation was identified as a potential resistance mechanism.
Additional Molecular Mechanisms
- Gene Regulatory Mechanisms: Amplifications affecting AR activity and various oncogenic drivers.
- Protein Homeostasis: Alterations in protein degradation pathways affecting AR stability.
- MicroRNAs: Several miRNAs augment AR activity and involvement in resistance mechanisms.
Temporal Dynamics of Resistance
The timing of resistance mechanisms varies across different patients and conditions. Many resistance mechanisms are pre-existing, but certain amplifications and alterations increase during treatment, demonstrating evolution based on therapeutic pressures.
Therapeutic Targeting Strategies
Direct AR Targeting
- Next-generation AR antagonists and degradation enhancers.
Combination Strategies with Enzalutamide
Including PARP inhibitors, EZH2 inhibitors, and metabolic inhibitors in clinical trials.
Drug Repurposing and Novel Agents
Examples include Artesunate and novel AR antagonists showing efficacy in preclinical studies.
Synthesis
The enzalutamide resistance landscape shows substantial heterogeneity across various mechanisms, necessitating careful interpretation of dominant mechanisms in clinical contexts. Understanding the specific mechanisms is essential for developing effective and personalized treatment strategies.